Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like a maze of trial data, cash-burn tables, and nuanced FDA language—especially when Phathom Pharmaceuticals’ disclosures dive deep into vonoprazan chemistry and GI risk factors. If you have ever asked, “How do I navigate Phathom Pharmaceuticals SEC filings explained simply?” this page was built for you.
Stock Titan’s AI instantly converts dense 10-K narratives into plain-English highlights and flags the trial milestones that move the needle. Need the Phathom Pharmaceuticals quarterly earnings report 10-Q filing without scouring EDGAR? Our real-time feed delivers it alongside ratio analyses and segment commentary. Curious about Phathom Pharmaceuticals insider trading Form 4 transactions? Receive Phathom Pharmaceuticals Form 4 insider transactions real-time alerts that outline which executives bought or sold shares and why it matters. You can also explore the Phathom Pharmaceuticals proxy statement executive compensation section to see how milestones influence pay, or read an Phathom Pharmaceuticals 8-K material events explained summary minutes after submission.
Every filing type—10-K, 10-Q, 8-K, S-3, and more—is covered, but we go further by tying them back to vonoprazan’s commercial runway. Our AI shows where cash burn intersects with Phase III trial timelines, delivers a Phathom Pharmaceuticals annual report 10-K simplified overview, and pairs it with an easy-to-follow Phathom Pharmaceuticals earnings report filing analysis. By understanding Phathom Pharmaceuticals SEC documents with AI, analysts can monitor Phathom Pharmaceuticals executive stock transactions Form 4, compare R&D outlays quarter-over-quarter, and gauge the impact of each GI pipeline update—all without reading 200 pages of technical prose.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 3,762,044 shares of Phathom Pharmaceuticals, Inc. (PHAT), representing 5.3% of the outstanding common stock, via a Schedule 13G filed in connection with an 08/11/2025 event. The filing shows shared voting and dispositive power over the disclosed shares and includes a joint filing agreement as Exhibit I. Signatures on the filing were provided by Gil Raviv on behalf of the two management entities and by Israel A. Englander, dated 08/12/2025.
The filing includes a certification that the securities were not acquired to change or influence control of Phathom. All ownership figures and classifications are provided directly on the cover pages and in Item 4 of the Schedule 13G.
Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.
Key transaction details:
- Granted 210,000 stock options to purchase common stock
- Exercise price set at $9.47 per share
- Grant date: June 23, 2025
- Expiration date: June 22, 2035
The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.
Anne Marie Cook has filed an initial Form 3 Statement of Beneficial Ownership following her appointment as Chief Legal Officer & Corporate Secretary at Phathom Pharmaceuticals (PHAT). The filing, dated June 28, 2025, discloses her beneficial ownership status as of June 23, 2025.
Key details of the filing:
- Cook currently owns no securities of Phathom Pharmaceuticals
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- The filing is made as an individual submission, not as part of a group
- Direct ownership form is indicated for the zero securities position
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transaction reporting.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
